Is GALT a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

408 people get GALT articles and Market Currents by email alert.

Get email alerts on GALT »

HEADLINES:

Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders

PR Newswire (Wed, 8:00AM)
Galectin Therapeutics Reports First Quarter 2013 Financial Results

PR Newswire (May 10, 2013)
Galectin Therapeutics Gets A Bid After Promising Results
Brian L. Wilson • Wed, May 1
Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies

PR Newswire (Apr 29, 2013)
2 Biotech Stocks Announcing Key Early Stage Clinical Developments
Heather Ingrassia • Wed, Apr 17 • 1 Comment
Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and Cirrhosis

PR Newswire (Apr 17, 2013)
Clinical Trial Sites for First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Announced by Galectin Therapeutics

PR Newswire (Apr 9, 2013)
Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley

PR Newswire (Apr 4, 2013)
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results

PR Newswire (Mar 29, 2013)
Galectin Therapeutics - Great Buying Opportunity
Peak Performance • Wed, Mar 27 • 10 Comments
Galectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis

PR Newswire (Mar 5, 2013)
Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia

Business Wire (Feb 19, 2013)
Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The RedChip Money Report” on FOX Business News

Business Wire (Feb 7, 2013)
2 Small-Cap Biotech Companies With Zero Debt And At Least $10 Million In Cash
Matt Schilling • Fri, Feb 1 • 6 Comments
Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease

Business Wire (Jan 31, 2013)
Galectin Therapeutics Inc. Announces Publication of Galectin Symposium Proceedings by the American Chemical Society

Business Wire (Jan 28, 2013)
New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in Preclinical Studies

Business Wire (Jan 22, 2013)
Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance

Business Wire (Jan 15, 2013)
Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis

Business Wire (Nov 26, 2012)
Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012

Business Wire (Nov 12, 2012)

To learn more about Seeking Alpha Pro, click here.

Galectin Therapeutics Gets A Bid After Promising Results
Brian L. Wilson • Wed, May 1
Galectin Therapeutics - Great Buying Opportunity
Peak Performance • Wed, Mar 27 • 10 Comments

2 Biotech Stocks Announcing Key Early Stage Clinical Developments
Heather Ingrassia • Wed, Apr 17 • 1 Comment
2 Small-Cap Biotech Companies With Zero Debt And At Least $10 Million In Cash
Matt Schilling • Fri, Feb 1 • 6 Comments
4 Biotechs Targeting Fibrosis
Steven Breazzano • Wed, Oct 17, 2012 • 4 Comments
5 Healthcare Companies With Insider Buying During October 2012
Markus Aarnio • Mon, Oct 15, 2012 • 2 Comments
Speculative $3 Stock Gets Important FDA Approval And Has Heavy Insider Buying
Bret Jensen • Tue, Jul 24, 2012 • 13 Comments
5 Healthcare Companies With Insider Buys For The Week Ending July 20th
Markus Aarnio • Sun, Jul 22, 2012 • 5 Comments
Pharmaceutical And Biotechnology Companies Purchased By Insiders Today
Gutone • Thu, Jun 21, 2012

There are no Transcripts on GALT.

Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders

PR Newswire (Wed, 8:00AM)
Galectin Therapeutics Reports First Quarter 2013 Financial Results

PR Newswire (May 10, 2013)
Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies

PR Newswire (Apr 29, 2013)
Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and Cirrhosis

PR Newswire (Apr 17, 2013)
Clinical Trial Sites for First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Announced by Galectin Therapeutics

PR Newswire (Apr 9, 2013)
Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley

PR Newswire (Apr 4, 2013)
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results

PR Newswire (Mar 29, 2013)
Galectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis

PR Newswire (Mar 5, 2013)
Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia

Business Wire (Feb 19, 2013)
Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The RedChip Money Report” on FOX Business News

Business Wire (Feb 7, 2013)
Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease

Business Wire (Jan 31, 2013)
Galectin Therapeutics Inc. Announces Publication of Galectin Symposium Proceedings by the American Chemical Society

Business Wire (Jan 28, 2013)
New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in Preclinical Studies

Business Wire (Jan 22, 2013)
Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance

Business Wire (Jan 15, 2013)
Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis

Business Wire (Nov 26, 2012)
Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012

Business Wire (Nov 12, 2012)
Galectin Therapeutics Reports Third Quarter 2012 Financial Results

Business Wire (Nov 9, 2012)
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012

Business Wire (Oct 26, 2012)
Galectin Therapeutics Hosted International Conference on Galectins and Disease

Business Wire (Sep 20, 2012)
Galectin Therapeutics Announces Relocation of Corporate Headquarters to Atlanta, GA

Business Wire (Aug 31, 2012)

GALT vs. ETF Alternatives

Company Description

Currently, there's no company description for GALT.

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 4:07 PM Galectin Therapeutics (GALT): Q1 EPS of -$0.22 misses by $0.04. (PR) Comment! [Earnings, Breaking News]
Monday, April 29, 12:56 PM Midday top 10 gainers: OSH +43%. WRLS +31%. CPTS + 19%. MDSO +20%. GALT +19%. LEDS +18%. FXEN +17%. OSBC +14%. PRGN +12%. CCH +12%.
Midday top 10 losers: LAS -31%. NTE -28%. HGSH -20%. GWAY -19%. LXRX -18%. FVE -15%. AUXL -11%. MLP -10%. CETV -10%. BIOL -10%. Comment! [On the Move]
Monday, April 29, 12:22 PM Shares of Galectin Therapeutics (GALT +20%) are on a tear today after the company released pre-clinical test results of the drugs GR-MD-02 and GM-CT-01, which were found to reverse the most advanced stage of liver cirrhosis, as well as reduction in portal hypertension in animal experiments. The results are seen as demonstrating an important pathophysiological effect of cirrhosis, and show encouraging potential for future human studies. 2 Comments [Healthcare, On the Move]
Wednesday, April 17, 11:14 AM Galectin Therapeutics (GALT +7.6%) gains after announcing it will present evidence gathered during pre-clinicals that its drugs can reverse liver fibrosis and cirrhosis at the International Liver Congress on April 27. The company says positive data is "accumulating" that its galactic inhibitor drugs are effective. Comment! [Healthcare, On the Move]
Tuesday, March 5, 1:37 PM Galectin Therapeutics (GALT +12%) ramps higher after saying it's received the go ahead from the FDA to proceed with Phase 1 clinical trials of GR-MD-02, a treatment for non-alcoholic fatty liver disease with advanced fibrosis. The study will be conducted in up to seven centers in the U.S., with enrollment and infusion of the first cohort to begin in May, 2013. Comment! [Healthcare, On the Move]
Monday, February 25, 12:53 PM Midday top 10 gainers: ENMD +26%. OBCI +25%. GALT +19%. APPY +15%. NTWK +12%. BKS +12%. ZNGA +11%. HXM +10%. MGN +10%. CMGE +9%.
Midday top 10 losers: AFFY -86%. CEDC -55%. DVAX -33%. GGS -31%. GMXR -24%. TROV -17%. EMITF -16%. ESI -14%. FRO -14%. XRSC -13%. Comment! [On the Move]
Monday, February 11, 12:45 PM Midday top 10 gainers: OBT +37%. ZN +22%. MLNK +17%. OESX +14%. MDCI +13%. MCBC +13%. UNXL +11%. XRSC +11%. DMND +11%. IEP +11%.
Midday top 10 losers: NVO -15%. GMXR -14%. DSKX -11%. ESTE -10%. AMBO -10%. CRVP -9%. ALCS -8%. GALT -8%. HEK -8%. BIOL -8%. Comment! [On the Move]
Friday, February 8, 1:00 PM Midday top 10 gainers: BDCO +32%. CZR +25%. ONCY +23%. LNKD +20%. SNCR +19%. GALT +13%. ZN +13%. FLT +12%. ZNGA +12%. ATVI +11%.
Midday top 10 losers: ETRM -55%. MSON -22%. GUID -21%. NUAN -19%. RVBD -18%. QKLS -16%. JE -14%. NSP -13%. STS -11%. SPWR -10%. Comment! [On the Move]
Thursday, January 31, 1:24 PM Galectin Therapeutics (GALT -3.4%) says it's submitted an Investigational New Drug application to the FDA to support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis with advanced fibrosis, or fatty liver disease. Comment! [Healthcare, On the Move]
Wednesday, January 16, 12:45 PM Midday top 10 gainers: CLRO +49%. NVTL +17%. HPTX +16%. FSGI +16%. CBK +14%. PLBC +13%. BOSC +13%. FSI +12%. CYTR +10%. ADES +10%.
Midday top 10 Losers: GALT -9%. LODE -8%. AMRS -8%. PGNX -8%. IRWD -7%. CROX -7%. GDOT -7%. AXX -7%. YOD -7%. AIM -7%. Comment! [On the Move]
Monday, November 26, 2012, 2:40 PM Galectin Therapeutics (GALT +14.4%) receives a Notice of Allowance from the USPTO for a patent of study "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies". The patent covers use of the company's galactomannan-based carbohydrate galectin inhibitor compounds, for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis. Comment! [Healthcare, On the Move]
Monday, November 26, 2012, 12:45 PM Midday top 10 gainers: CBAK +80%. ENMD +23%. ANAD +19%. SSE +17%. HOGS +16%. SBLK +15%. CLSN +14%. SOMX +15%. GALT +14%. ACRX +12%. Midday top 10 Losers: SAB -14%. MMR -13%. CNIT -12%. CCCL -14%. BZ -9%. ZLC -9%. OXF -8%. MEIP -8%. PSTR -8%. AXX -7%. Comment!
Wednesday, August 29, 2012, 3:28 PM Galectin Therapeutics ((GALT -7.4%) slides after naming Harold H. Shlevin as the company's new COO as of October 1, 2012. Mr.Shlevin succeeds Maureen Foley, one of the company's co-founders, who served as its COO and corporate secretary. 2 Comments [Healthcare, On the Move]
Wednesday, July 25, 2012, 9:16 AM Premarket gainers: RVBD +26%. ACOM +16%. LL +14%. VHC +13%. INVN +13%. REGN +13%. ALTR +11%. SYMC +10%. DEXO +10%. SPPI +10%. TPX +9%. PSTI +8%. PNRA +8%. GALT +8%. JNPR +7%. ARMH +7%. ALXN +6%. BRCM +6%. STEM +5%.
Losers: RSH -22%. NFLX -20%. TRIP -15%. IGT -12%. BWLD -11%. RFMD -10%. WLP -10%. USG -6%. WFT -6%. Comment! [On the Move]
Monday, July 23, 2012, 11:05 AM Microcap drug developer Galectin Therapeutics (GALT +68%) soars after being granted a patent for its Galactose-prolonged polysaccharides, a carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis. 2 Comments [Healthcare, On the Move]

GALT Galectin Therapeutics, Inc.

GALT

Galectin Therapeutics, Inc.